The share price of Novacyt (LON: NCYT), the clinical diagnostics specialist and AIM’s top performer in 2020, tumbled 40% today on news that it is dispute with Department of Health and Social Care (DHSC).
Background
On 29 September 2020, Novacyt announced a second supply contract with the DHSC for its exsig®COVID-19 Direct kits and other products. In an earlier trading update on 29 January 2021, it explained it was in active discussions with the DHSC regarding an…
Sign up and read the full article
Register to continue reading our content.
Get FREE access now
Already a member? Login
Previous article
Next article
More on Novacyt SA
30/09/2022 · Company Insights
Having survived a near death experience several years ago, a manufacturer of specialist industrial equipment covered…
17/06/2022 · Company Insights
Some welcome good news at last for shareholders in this provider of online competitions to win…
More Company Insights
A bright start to the week for these AIM companies
An impressive trading update brings another upgrade
A high-quality AIM company continues to deliver
More on Novacyt SA
More Company Insights